ex-vivo-functional-1920x640
Whitepaper

Ex Vivo Functional Drug Testing of 3D Patient-Derived Cancer Cells Shows Promise for Personalized Medicine

Researchers at the Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, are demonstrating how functional screening of 3D patient-derived cancer cells enables effective drug sensitivity testing and the ability to potentially tailor medicines to an individual patient.

We spoke to a Senior Scientist and Principal Investigator from FIMM, to hear more about their approach. Read the whitepaper to find out what they said.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Ex Vivo Functional Drug Testing of 3D Patient-Derived Cancer Cells Shows Promise for Personalized Medicine

Download Whitepaper